Special Issue

New Perspectives in the Treatment of Thoracic Cancers

Message from the Guest Editors

Thoracic cancers encompass a wide category of malignancies that arise from several different organs. While primary or secondary lung tumors represent the vast majority of intrathoracic cancers, with an impressively high burden of morbidity and mortality. tumors arising from the thymus or pleura are less common but offer engaging insights on the relationship between cancer and host. Historically, tumors in early stages are usually treated with surgery upfront, while multimodality approaches represent the key in the management of more advanced cancer conditions. However, recent technological advancements, the introduction of novel, highly effective anticancer molecules, and the inceptive application of artificial intelligence (AI) protocols in medical sciences have enhanced our understanding and re-drawn our perspectives in the treatment of intrathoracic malignancies. The scope of this Special Issue is therefore to discover the most recent achievements and findings in the treatment of thoracic malignancies and to explore their potential impact in redefining the current management guidelines of these conditions.

Guest Editors

Dr. Francesco Londero

Division of Thoracic Surgery, Cardiothoracic Department, University Hospital of Udine, 33100 Udine, Italy

Dr. Francesco Guerrera

Department of Cardio-Thoracic and Vascular Surgery, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

Deadline for manuscript submissions

closed (1 September 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/214957

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

